|
Synonyms: AVI-3207 | AVI3207 | N2-acetyl-L-arginyl-L-leucyl-L-tyrosyl-L-glutamic acid
Compound class:
Peptide or derivative
Comment: Timtraxanib (AVI-3207) is an angiogenesis inhibitor [2]. Structurally it is modified tetrapeptide that acts as a selective VEGF receptor-2 (VEGFR-2) inhibitor [1,3-4]. The N terminal acylation improves the peptide's stability against serum peptidase degradation [5]. Functionally, timtraxanib blocks VEGFR-2-mediated neovascularization, whilst sparing the function of VEGFR-1. Intravitreal administration of timtraxanib reduces neovascularization in animal models of age-related macular degeneration.
|
Classification  |
|
| Compound class | Peptide or derivative |
| International Nonproprietary Names |
|
| INN number | INN |
| 11706 | timtraxanib |
| Synonyms |
| AVI-3207 | AVI3207 | N2-acetyl-L-arginyl-L-leucyl-L-tyrosyl-L-glutamic acid |
| Database Links |
|
| GtoPdb PubChem SID | 442878699 |
| Search PubMed clinical trials | timtraxanib |
| Search PubMed titles | timtraxanib |
| Search PubMed titles/abstracts | timtraxanib |
